Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
Vigil Neuroscience, Inc. (VIGL)
Company Research
Source: GlobeNewswire
- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer’s Disease on track for first quarter of 2025 - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024, and provided an update on recent progress. “Our accomplishments in the third quarter have provided significant momentum as we continue to progress our two differentiated TREM2 agonists through clinical development with the goal of reaching patients as quickly as possible,” said Ivana Magovcevic-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “We believe our strategic positioning of iluzanebart in ALSP and VG-
Show less
Read more
Impact Snapshot
Event Time:
VIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIGL alerts
High impacting Vigil Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
VIGL
News
- Vigil Neuroscience to Present at Upcoming Investor ConferencesGlobeNewswire
- Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its price target raised by analysts at Wedbush from $23.00 to $24.00. They now have an "outperform" rating on the stock.MarketBeat
- Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake [Yahoo! Finance]Yahoo! Finance
- Vigil Neuroscience to Present at Guggenheim Healthcare Innovation ConferenceGlobeNewswire
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)PR Newswire
VIGL
Earnings
- 11/7/24 - Beat
VIGL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- VIGL's page on the SEC website